日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

普拉替尼治疗晚期RET融合阳性非小细胞肺癌患者的I/II期ARROW研究的最终疗效和安全性数据

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-01489
Besse, Benjamin; Subbiah, Vivek; Curigliano, Giuseppe; Bowles, Daniel W; Doebele, Robert C; Mansfield, Aaron S; Baik, Christina S; de Lima Lopes, Gilberto; Paz-Ares, Luis; Taylor, Matthew H; Tan, Daniel S W; Alonso, Guzman; Gadgeel, Shirish M; Kalemkerian, Gregory P; Ou, Sai-Hong Ignatius; van der Wekken, Anthonie J; Becerra, Carlos R; Evangelist, Makenzi; Griesinger, Frank; Liu, Stephen V; Lou, Yanyan; Mazières, Julien; Melear, Jason M; Narang, Mohit; Saxena, Ashish; Thomas, Michael; Wang, Sophia; Thomassen, Amber; Lee, Dae Ho; Kim, Dong-Wan; Gainor, Justin F
细胞生物学
肺癌
肿瘤
RET
肿瘤免疫
发表日期：2026
文献求助 收藏

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Zenocutuzumab治疗NRG1融合阳性癌症的疗效

期刊:New England Journal of Medicine
影响因子:78.5
doi:10.1056/NEJMoa2405008
Schram, Alison M; Goto, Koichi; Kim, Dong-Wan; Macarulla, Teresa; Hollebecque, Antoine; O'Reilly, Eileen M; Ou, Sai-Hong Ignatius; Rodon, Jordi; Rha, Sun Young; Nishino, Kazumi; Duruisseaux, Michaël; Park, Joon Oh; Neuzillet, Cindy; Liu, Stephen V; Weinberg, Benjamin A; Cleary, James M; Calvo, Emiliano; Umemoto, Kumiko; Nagasaka, Misako; Springfeld, Christoph; Bekaii-Saab, Tanios; O'Kane, Grainne M; Opdam, Frans; Reiss, Kim A; Joe, Andrew K; Wasserman, Ernesto; Stalbovskaya, Viktoriya; Ford, Jim; Adeyemi, Shola; Jain, Lokesh; Jauhari, Shekeab; Drilon, Alexander
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Lunar farside volcanism 2.8 billion years ago from Chang'e-6 basalts

28亿年前月球背面嫦娥六号玄武岩火山活动

期刊:Nature
影响因子:48.5
doi:10.1038/s41586-024-08382-0
Zhang, Qian W L; Yang, Mu-Han; Li, Qiu-Li; Liu, Yu; Yue, Zong-Yu; Zhou, Qin; Chen, Liu-Yang; Ma, Hong-Xia; Yang, Sai-Hong; Tang, Xu; Zhang, Guang-Liang; Ren, Xin; Li, Xian-Hua
发表日期：2025
文献求助 收藏

The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial

双位阻 mTORC1 选择性抑制剂 RMC-5552 在晚期实体瘤中的应用：一项 1 期临床试验

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-2112
Schram, Alison M; Naqash, Abdul Rafeh; Haura, Eric B; Riess, Jonathan W; Ulahannan, Susanna V; Ou, Sai-Hong I; Munster, Pamela N; Cheng, Michael L; Gustafson, W Clay; Bitman, Bojena; Friedman, Robert; Penn, Ruth; Kar, Sumit; Seshadri, Vidya; Wang, Zhican; Tao, Lin; Yang, Yu Chi; Singh, Mallika; Burris, Howard A; Meyerowitz, Justin G
mTOR
ORC1
发表日期：2025
文献求助 收藏

YOLO-LF: application of multi-scale information fusion and small target detection in agricultural disease detection

YOLO-LF：多尺度信息融合和小目标检测在农业病害检测中的应用

期刊:Frontiers in Plant Science
影响因子:4.8
doi:10.3389/fpls.2025.1609284
Wang, Xinming; Tang, Sai Hong; Mohd Ariffin, Mohd Khairol Anuar B; Ismail, Mohd Idris Shah B; Shen, Jiazheng
发表日期：2025
文献求助 收藏

The User's Guide to Amivantamab

阿米万单抗用户指南

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-025-01128-6
Brazel, Danielle; Smith, Janellen; Ou, Sai-Hong Ignatius; Nagasaka, Misako
发表日期：2025
文献求助 收藏

A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025

2025年左右对中国已批准用于治疗MET外显子14剪接位点突变（METex14+）非小细胞肺癌的MET TKI（赛沃替尼、古马替尼、维布瑞替尼、替泊替尼、卡马替尼）进行简要回顾

期刊:Lung Cancer: Targets and Therapy
影响因子:3.3
doi:10.2147/LCTT.S547090
Hu, Yanyan; Ou, Sai-Hong Ignatius
肺癌
肿瘤
肿瘤免疫
细胞生物学
MET
发表日期：2025
文献求助 收藏

Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib

吉瑞替尼成功且持续地控制了一名ALK阳性非小细胞肺癌脑转移患者的长期疾病（>24个月），该患者此前接受过多种ALK TKI治疗后病情进展。病例报告及吉瑞替尼相关文献综述。

期刊:Lung Cancer: Targets and Therapy
影响因子:3.3
doi:10.2147/LCTT.S547128
Ou, Sai-Hong Ignatius; Park, Cathleen June; Arter, Zhaohui Liao; Nagasaka, Misako
肺癌
肿瘤
肿瘤免疫
ALK
神经科学
细胞生物学
发表日期：2025
文献求助 收藏

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

LAURA 研究完成了奥希替尼治疗 EGFR+ NSCLC 从 IB 期到 IV 期的拼图：与安慰剂相比，辅助奥希替尼治疗显著改善了不可切除的 III 期 EGFR 突变 NSCLC 患者的 PFS 和 CNS 进展（LAURA，NCT03521154）

期刊:Lung Cancer: Targets and Therapy
影响因子:3.3
doi:10.2147/LCTT.S520833
Luo, Faustine X; Arter, Zhaohui; Ou, Sai-Hong Ignatius; Nagasaka, Misako
EGFR
EGF
CLC
发表日期：2025
文献求助 收藏

Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report

肠促胰素受体激动剂索玛鲁肽治疗阿来替尼引起的体重过度增加：病例报告

期刊:Lung Cancer: Targets and Therapy
影响因子:3.3
doi:10.2147/LCTT.S549011
Lee, Alexandria T M; Park, Cathleen June; Arter, Zhaohui Liao; Nagasaka, Misako; Ou, Sai-Hong Ignatius
信号转导
发表日期：2025
文献求助 收藏